Eli Lilly and Company Buyback
OLI recorded this information on 12/17/2012
Eli Lilly and Company
The Lilly board of directors also authorized the initiation of a new $1.5 billion share repurchase program, which the company anticipates completing in 2013. The company recently completed a $3.0 billion share repurchase program that was started in 2000. All purchases under the new $1.5 billion share repurchase program will be made on the open market at prevailing prices. Purchases will be made over a period to be determined by management of the company. Shares acquired will be retired.
Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
Eli Lilly SEC Filing Email Alerts Service
Open the LLY Page at The Online Investor »
Strong Buy (3.67 out of 4)